Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors
作者:David B. Belanger、Michael J. Williams、Patrick J. Curran、Amit K. Mandal、Zhaoyang Meng、Matthew P. Rainka、Tao Yu、Neng-Yang Shih、M. Arshad Siddiqui、Ming Liu、Seema Tevar、Suining Lee、Lianzhu Liang、Kimberly Gray、Bohdan Yaremko、Jennifer Jones、Elizabeth B. Smith、Dan B. Prelusky、Andrea D. Basso
DOI:10.1016/j.bmcl.2010.08.140
日期:2010.11
We report a series of potent imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Optimization of the solvent accessible 8-position led to improvements in both oral bioavailability and off-target kinase inhibition. Compound 25 demonstrates anti-tumor activity in an A2780 ovarian tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.